Markets:

Overview

News

Currencies

International

Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

7.110 -0.070 (-0.97%)

Streaming Delayed Price Updated: 10:30 AM EDT, May 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Precision BioSciences, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Preview: Precision BioSciences's Earnings ↗

May 08, 2023

Via Benzinga

Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023

May 02, 2023

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023

April 20, 2023

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting

April 19, 2023

From Precision BioSciences, Inc.

Via Business Wire

Looking Into Precision BioSciences's Return On Capital Employed ↗

March 14, 2023

Via Benzinga

Preview: Precision BioSciences's Earnings ↗

March 08, 2023

Via Benzinga

Precision BioSciences Earnings Perspective: Return On Capital Employed ↗

December 06, 2022

Via Benzinga

Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease

April 13, 2023

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference

March 27, 2023

From Precision BioSciences, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023 ↗

March 14, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 14, 2023

Tuesday's morning session saw 84 companies set new 52-week lows.

Via Benzinga

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

March 09, 2023

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023

March 02, 2023

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes

February 24, 2023

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference

February 22, 2023

From Precision BioSciences, Inc.

Via Business Wire

There's a Lot of Upside For Emerging Gene-Editing Companies

February 21, 2023

These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come.

Via MarketBeat

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

February 14, 2023

From Precision BioSciences, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

February 06, 2023

Via Benzinga

Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones

January 09, 2023

From Precision BioSciences

Via Business Wire

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate

January 06, 2023

From Precision BioSciences, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

December 23, 2022

OnFriday, 143 stocks hit new 52-week lows.

Via Benzinga

Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

December 10, 2022

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Change to its Board of Directors

November 10, 2022

From Precision BioSciences, Inc.

Via Business Wire

Coinbase To $80? Plus Deutsche Bank Cuts PT On This Stock By 80% ↗

November 10, 2022

Citigroup cut the price target on Coinbase Global, Inc. (NASDAQ: COIN) from $105 to $80. Citigroup analyst Peter Christiansen maintained a Buy rating on the stock. Coinbase shares rose 2.1% to $46.95...

Via Benzinga

Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update

November 08, 2022

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences's Earnings Outlook ↗

November 07, 2022

Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

November 04, 2022

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting

November 03, 2022

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022

November 02, 2022

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

October 26, 2022

From Precision BioSciences, Inc.

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.